Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

As Novo Nordisk and Pfizer fight over a promising GLP-1 pipeline at Metsera, Amgen is staying the course on its antibody-peptide conjugate MariTide, which the company is taking into late-stage ...

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the ...

The appetite for weight-loss drugs, known as glp-1 agonists, has been insatiable since they hit the market a decade ago. In 2024 global spending on them reached $54bn, a figure that is sure to rise in ...

Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as he remarked: “Look, I think Amgen needs to do ...